Zolbetuximab Claudin18.2 Positive, HER2 Negative, Advanced Gastric Cancer
NCT06767449 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 80
Last updated 2025-01-09
Summary
* Treatment effectiveness in the real world
* Adverse effects
* Tissue samples collected (multiplex IHC to assess PD-L1 expression, MMR gene status, and Claudin18.2)
* Blood samples collected (ctDNA, scRNAseq, or immune cell profiling)
Conditions
- Advanced Gastric Cancer
Sponsors & Collaborators
-
Yonsei University
lead OTHER
Principal Investigators
-
Sun Young Rha · Severance Hospital
Eligibility
- Min Age
- 19 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-12-01
- Primary Completion
- 2026-12-01
- Completion
- 2026-12-01
Countries
- South Korea
Study Locations
More Related Trials
-
SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma
NCT05218148 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study of the Effectiveness and Safety of Nivolumab Plus Chemotherapy in Participants With Untreated Advanced/Recurrent Gastric Cancer
NCT05334719 ·Status: ACTIVE_NOT_RECRUITING
-
A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer
NCT03505320 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Trastuzumab Based Therapy in HER2 Positive AGC
NCT03024450 ·Status: COMPLETED
-
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
NCT06551142 ·Status: RECRUITING ·Phase: PHASE1
-
First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)
NCT05749900 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer
NCT03776487 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Immune Checkpoint Inhibitors (ICIs) Retreatment in Second-line Treatment of Advanced Gastric Cancer: a Retrospective, Real-world Study
NCT06814548 ·Status: NOT_YET_RECRUITING
-
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
NCT03653507 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Efficacy and Safety of Neoadjuvant Sintilimab Plus FLOT Versus Sintilimab Plus SOX Phase II Clinical Trial for Patients With Locally Advanced Gastric Cancer
NCT06459921 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for Advanced Gastric Cancer
NCT01671449 ·Status: COMPLETED ·Phase: PHASE3
-
First-Line and Neoadjuvant Immunotherapy for Gastric Cancer
NCT06727981 ·Status: RECRUITING
-
Early Access Program for Zolbetuximab
NCT06048081 ·Status: AVAILABLE
-
Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence
NCT03443856 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Nivolumab Plus Chemotherapy in First Line Treatment of Adult Participants With Advanced or Metastatic Gastric Cancer
NCT05165264 ·Status: ACTIVE_NOT_RECRUITING
-
Evaluating the Safety and Efficacy of SB Injection in Patients With Advanced or Metastatic Gastric Cancer
NCT01305993 ·Status: UNKNOWN ·Phase: PHASE2
-
Nivolumab Combined With SOX Used in the Perioperative Treatment
NCT05739045 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer
NCT01671774 ·Status: COMPLETED ·Phase: PHASE1
-
IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer
NCT03918499 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC
NCT06439550 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer
NCT01260194 ·Status: TERMINATED ·Phase: PHASE4
-
A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers
NCT06422403 ·Status: RECRUITING ·Phase: PHASE2
-
The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer
NCT06235164 ·Status: ACTIVE_NOT_RECRUITING
-
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
NCT05111626 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC
NCT04168931 ·Status: TERMINATED ·Phase: PHASE2